- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02764697
Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Uveitis represents a heterogeneous group of diseases that results from ocular inflammatory reaction involving ocular tissue and vasculature. The inflammation usually causes pain, redness, photophobia and blurred vision.
H.P Acthar Gel stimulate the adrenal cortex to secrete cortisol. Additionally H.P. Acthar gel is also reported to bind to melanocortin receptors. Melanocortin receptor activation has been shown to exert marked anti-inflammatory and immune-modulatory effects in animal studies, by modulating pro inflammatory cytokines, followed by induction of anti- inflammatory mediators and subsequent leukocyte migration. Specifically melanocortins down regulate Tumor Necrosis Factor (TNF) alpha, Interleukin (IL) -2, Interferon gamma and T-cell proliferation and upregulates IL-10 and regulatory T cells. For this reason H.P. Acthar is an approved treatment for ocular inflammatory disease.
Ocular inflammatory disease is typically treated with regional or systemic therapy. The regional therapy typically consists of topical corticosteroids or periocular or regional corticosteroids. Regional therapy can lead to a steroid response glaucoma, which is increased intraocular pressure.This pilot study aims to evaluate the possible effectiveness of H.P. Acthar in patients with active ocular inflammatory disease, and currently on treatment for glaucoma or have a history of glaucoma.
Subjects will be treated with H P Acthar subcutaneous gel, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses with the same cumulative units to be administered, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
This will be a prospective open-label, non-randomized pilot study: 12 week treatment for active non-infectious uveitis, endpoint assessment and safety assessment; additional 12 week assessment for uveitis activity/quiescence and safety assessment.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Florida
-
Saint Petersburg, Florida, United States, 33709
- Tampa Bay Uveitis Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has the ability to understand and sign the informed consent document
- Subject is 18 years of age or older
- Subject can be male or female
- Subject has negative Purified Protein Derivative (Tuberculosis skin test) or quantiferon TB Gold Test (blood test for TB) testing done in 3 months
- Subject has active ocular inflammation in at least one eye
- Subject has visual acuity in at least one eye of 20/400 or better.
- Subject has a history of glaucoma or has actively treated glaucoma
- Subject is willing and able to comply with the study procedures
- Female subjects of childbearing potential must not be pregnant or breast-feeding, must have a negative pregnancy test at screening and must be willing to undergo pregnancy testing throughout the study
Exclusion Criteria:
- Subject has any ocular infection
- Subject has any systemic infection
- Participant has documented immunocompromised or immune-incompetent state
- Subject has any ocular co-morbidity than prevents assessment of intraocular inflammation
- Subject has had any intra-ocular surgery in previous 6 weeks
- Subject has any planned elective surgery ocular or systemic during study duration
- Subject is pregnant or breast-feeding
- Subject had a recent vaccination with live or attenuated vaccines
- Subject has a sensitivity to Porcine derived proteins
- Subject has a medical history which is a contraindication to receiving H.P. Acthar
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: H.P. Acthar Subcutaneous Gel Injection
For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
|
Subcutaneous injection twice weekly
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography
Time Frame: 12 Weeks
|
Subjects will have fundus photography at baseline and 12 weeks.
Intermediate uveitis is graded by haze; it is done using the photographic scale: grades 0-4 (lower values are a better outcome), utilized by the SUN criteria, based on the Nussenblatt photographic vitreous haze scale
|
12 Weeks
|
Number of Participants With Clinically Significant Improvement of Macular Edema
Time Frame: 12 weeks
|
Clinically Significant Uveitic Macular Edema: Clinical Improvement of Macular Edema with OCT Documentation of central foveal thickness < 300 microns
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Grace L Clarke, Tampa Bay Uveitis Center, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Panuveitis
- Uveal Diseases
- Choroid Diseases
- Macular Degeneration
- Choroiditis
- Iris Diseases
- Scleral Diseases
- Macular Edema
- Uveitis
- Uveitis, Posterior
- Uveitis, Intermediate
- Pars Planitis
- Uveitis, Anterior
- Iridocyclitis
- Scleritis
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenocorticotropic Hormone
Other Study ID Numbers
- TBUC 10012015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uveitis
-
Priovant Therapeutics, Inc.Active, not recruitingNon-infectious Intermediate Uveitis | Non-infectious Posterior Uveitis | Non-infectious Pan UveitisUnited States
-
University of NebraskaUnknownPosterior Uveitis | Intermediate Uveitis | Pan-uveitisUnited States
-
CHU de Quebec-Universite LavalCompletedIntermediate Uveitis | Anterior UveitisCanada
-
Stanford UniversitySanten Inc.WithdrawnPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
EyePoint Pharmaceuticals, Inc.CompletedPanuveitis | Posterior Uveitis | Intermediate UveitisIndia
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
Duke UniversityCompletedPosterior Uveitis | Intermediate UveitisUnited States
-
AllerganCompletedPosterior Uveitis | Intermediate UveitisFrance, United Kingdom, United States, Spain, Poland, India, South Africa, Korea, Republic of, Canada, Czech Republic, Australia, Germany, Israel, Switzerland, Portugal, Austria, Brazil, Greece
-
Novartis PharmaceuticalsCompletedNon-infectious Intermediate Uveitis | Non-infectious Posterior Uveitis | Non-infectious PanuveitisUnited States, United Kingdom
-
Bausch & Lomb IncorporatedCompletedNoninfectious Posterior UveitisUnited States
Clinical Trials on H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
-
Stanford UniversityMallinckrodtCompletedKidney DiseasesUnited States
-
Ocular Immunology and Uveitis FoundationUnknownUveitis, Posterior | Vasculitis RetinalUnited States
-
Fiechtner, Justus J., M.D., P.C.CompletedLupus Erythematosus Systemic ExacerbationUnited States
-
University of Maryland, BaltimoreMallinckrodtCompleted
-
Mayo ClinicMallinckrodtCompletedIdiopathic Membranous NephropathyUnited States, Canada
-
Dent Neuroscience Research CenterCompletedChronic MigraineUnited States
-
MallinckrodtCompleted
-
The University of Texas Health Science Center,...CompletedMultiple Sclerosis (MS)United States
-
Fiechtner, Justus J., M.D., P.C.MallinckrodtUnknownPsoriatic ArthritisUnited States
-
Mamatha Pasnoor, MDMallinckrodtWithdrawnChronic Inflammatory Demyelinating PolyneuropathyUnited States